Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Genetic Risks for Bicuspid Aortic Valve Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
Siddharth Prakash, The University of Texas Health Science Center, Houston Identifier:
First received: March 27, 2013
Last updated: May 1, 2017
Last verified: May 2017
Bicuspid Aortic Valve (BAV) is the most common congenital heart malformation in adults, but very little is known about the genetic causes or risk factors for adverse outcomes. Currently, it is estimated that most cases of aortic stenosis in patients less than 65 years old are caused by BAVs. BAV patients are also at high risk to develop aneurysms of the ascending aorta, which may lead to aortic dissections. Dr. Prakash and his colleagues plan to use individual genetic information to identify persons with BAV who are at high risk for complications and to customize therapies.

Bicuspid Aortic Valve
Unicuspid Aortic Valve

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 10 Years
Official Title: Genetic Risks for Bicuspid Aortic Valve Disease

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Thoracic aortic aneurysms and dissections [ Time Frame: 10 years ]
    Development of new aneurysms and/or dissections of the thoracic aorta

  • Aortic valve replacement surgery [ Time Frame: 10 years ]

Secondary Outcome Measures:
  • Aortic enlargement [ Time Frame: 10 years ]
    Dilation of thoracic aorta, new or progressive

Other Outcome Measures:
  • Aortic valve degeneration [ Time Frame: 10 years ]
    Increase in valve degeneration score by at least 1 unit

Biospecimen Retention:   Samples With DNA
Genomic DNA from whole blood Genomic DNA from saliva Aortic valve tissue preserved in RNALater

Estimated Enrollment: 400
Study Start Date: March 2012
Estimated Study Completion Date: November 2022
Estimated Primary Completion Date: May 2021 (Final data collection date for primary outcome measure)
BAV Cohort
Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.

Detailed Description:
To be included in the study, patients must have a bicuspid or unicuspid aortic valve, documented by clinical history or imaging studies. If the aortic valve was replaced surgically, they may still be eligible. Participants will be asked to donate a single tube of blood and fill out a questionnaire. Patients will also be followed up by telephone or email about once a year to determine if they experience any medical complications related to Bicuspid Aortic Valve (BAV), such as aortic aneurysms, aortic dissections or valve disease. Patients may not be included if they are less than 18 years old at the time of recruitment or have a recognized genetic syndrome or genetic mutation such as Marfan or Ehlers-Danlos syndrome.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults at least 18 years old with unicuspid or bicuspid aortic valves

Inclusion Criteria:

  • At least 18 years of age
  • Diagnosis of bicuspid or unicuspid aortic valve

Exclusion Criteria:

  • Less than 18 years of age
  • Recognized syndrome or identified genetic mutation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01823432

Contact: Siddharth Prakash, MD, PhD 713-500-7003

United States, Texas
University of Texas Health Science Center Houston Recruiting
Houston, Texas, United States, 77030
Contact: Josephine Turner   
Principal Investigator: Siddharth Prakash, MD, PhD         
Sub-Investigator: Dianna Milewicz, MD, PhD         
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Principal Investigator: Siddharth Prakash, MD, PhD The University of Texas Health Science Center, Houston
  More Information

Additional Information:
Responsible Party: Siddharth Prakash, Assistant Professor - Internal Medicine, The University of Texas Health Science Center, Houston Identifier: NCT01823432     History of Changes
Other Study ID Numbers: BAV_Risks
Study First Received: March 27, 2013
Last Updated: May 1, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Heart Valve Diseases
Aortic Valve Stenosis
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction processed this record on May 22, 2017